BiotechTube

Cyclophosphamide + abatacept + Methotrexate + Tacrolimus

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

GVHD

Conditions

GVHD, Hematologic Neoplasms

Trial Timeline

Nov 26, 2019 → Jun 15, 2023

NCT ID
NCT03680092

About Cyclophosphamide + abatacept + Methotrexate + Tacrolimus

Cyclophosphamide + abatacept + Methotrexate + Tacrolimus is a phase 2 stage product being developed by Bristol Myers Squibb for GVHD. The current trial status is completed. This product is registered under clinical trial identifier NCT03680092. Target conditions include GVHD, Hematologic Neoplasms.

What happened to similar drugs?

0 of 5 similar drugs in GVHD were approved

Approved (0) Terminated (0) Active (5)
🔄Alpha-1 antitrypsin (AAT) + PlaceboCSLPhase 3
🔄Tacrolimus (Tac) + Methotrexate (MTX) + Ruxolitinib (Rux) + Cyclophosphamide + Mycophenolate mofetil (MMF)IncytePhase 3
🔄Itacitinib + Placebo + Prednisone + MethylprednisoloneIncytePhase 3
🔄Ruxolitinib + Extracorporeal photopheresis (ECP) + Low-dose methotrexate (MTX) + Mycophenolate mofetil (MMF) + mechanistic Target of Rapamycin (mTOR) inhibitors (everolimus or sirolimus) + Infliximab + Rituximab + Pentostatin + Imatinib + IbrutinibIncytePhase 3
🔄remestemcel-LMesoblastPhase 3

Hype Score Breakdown

Clinical
12
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT03680092Phase 2Completed

Competing Products

19 competing products in GVHD

See all competitors
ProductCompanyStageHype Score
Prednisone + Jakavi(ruxolitinib) + PrednisoneNovartisPhase 2
42
RituximabRochePhase 2
31
Efavaleukin AlfaAmgenPhase 1/2
24
AMG 592AmgenPhase 1
29
AMG 592AmgenPhase 1
29
milatuzumabGilead SciencesPhase 1
21
Itacitinib + Prednisone + MethylprednisoloneInnovent BiologicsPhase 1/2
24
ALD518 + ALD518 + ALD518CSLPhase 1/2
24
Alpha-1 antitrypsin (AAT) + PlaceboCSLPhase 3
40
Tacrolimus (Tac) + Methotrexate (MTX) + Ruxolitinib (Rux) + Cyclophosphamide + Mycophenolate mofetil (MMF)IncytePhase 3
44
RuxolitinibIncytePre-clinical
23
Itacitinib + Placebo + Prednisone + MethylprednisoloneIncytePhase 3
37
Ruxolitinib + PrednisoneIncytePhase 2
39
Itacitinib (200 mg) + Itacitinib (300 mg) + prednisone or methylprednisolone (corticosteroids)IncytePhase 1
26
Ruxolitinib + Extracorporeal photopheresis (ECP) + Low-dose methotrexate (MTX) + Mycophenolate mofetil (MMF) + mechanistic Target of Rapamycin (mTOR) inhibitors (everolimus or sirolimus) + Infliximab + Rituximab + Pentostatin + Imatinib + IbrutinibIncytePhase 3
37
Ruxolitinib + Prednisone or methylprednisoloneIncytePhase 2
32
RuxolitinibIncytePre-clinical
23
Itacitinib + TocilizumabIncytePhase 1
18
remestemcel-LMesoblastPhase 3
34